Skip to main content
Erschienen in: Wiener klinisches Magazin 4/2014

01.09.2014 | Onkologie

Lungenkarzinom

Molekulare Pathologie und personalisierte Therapie

verfasst von: A. Schultheis, J. Wolf, R. Büttner

Erschienen in: Wiener klinisches Magazin | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Tumorimmuntherapie hat in den letzten Jahren rasante Fortschritte gemacht. So lieferten Studien zur Behandlung des Bronchialkarzinoms mit „cancer vaccines“ wie dem melanomassoziierten Antigen A3 (MAGE-A3) und liposomalem BLP25 vielversprechende Ergebnisse in den Stadien IB/II und III des nichtkleinzelligen Bronchialkarzinoms. Immunmodulatorische Agenzien wie Talactoferrin oder Ipilimumab scheinen v. a. in Verbindung mit einer platinbasierten Chemotherapie zu wirken, was andeutet, dass insbesondere die Kombination von Immuntherapeutika, konventioneller Chemotherapie und tumorspezifischen, zielgerichteten Agenzien das größte therapeutische Zukunftspotenzial besitzt. Das genaue Verständnis der Interaktion zwischen Tumor und Immunsystem bleibt essenziell für die Identifizierung potenzieller Biomarker. Im Idealfall ermöglicht es auch im Bereich der Immuntherapie die Entwicklung gezielter Ansätze.
Literatur
1.
Zurück zum Zitat Macconaill LE (2012) Advancing personalized cancer medicine in lung cancer. Arch Pathol Lab Med 136:1210–1216PubMedCrossRef Macconaill LE (2012) Advancing personalized cancer medicine in lung cancer. Arch Pathol Lab Med 136:1210–1216PubMedCrossRef
2.
3.
Zurück zum Zitat Schiller JH et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98 Schiller JH et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98
4.
Zurück zum Zitat Sandler A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550 Sandler A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550
5.
Zurück zum Zitat Shepherd FA et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132 Shepherd FA et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132
6.
Zurück zum Zitat Mok TS et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957 Mok TS et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957
7.
Zurück zum Zitat Rosell R et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958–967 Rosell R et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958–967
8.
Zurück zum Zitat Kwak EL et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693–1703 Kwak EL et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693–1703
9.
10.
Zurück zum Zitat Topalian SL, Weiner GJ, Pardoll DM (2011) Cancer immunotherapy comes of age. J Clin Oncol 29:4828–4836 Topalian SL, Weiner GJ, Pardoll DM (2011) Cancer immunotherapy comes of age. J Clin Oncol 29:4828–4836
11.
Zurück zum Zitat Finn OJ (2008) Cancer immunology. N Engl J Med 358:2704–2715 Finn OJ (2008) Cancer immunology. N Engl J Med 358:2704–2715
12.
Zurück zum Zitat Murala S et al (2010) Current status of immunotherapy for the treatment of lung cancer. J Thorac Dis 2:237–244 Murala S et al (2010) Current status of immunotherapy for the treatment of lung cancer. J Thorac Dis 2:237–244
13.
Zurück zum Zitat Thomas A, Hassan R (2012) Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol 13:e301–e310PubMedCrossRef Thomas A, Hassan R (2012) Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol 13:e301–e310PubMedCrossRef
14.
Zurück zum Zitat Poschke I, Mougiakakos D, Kiessling R (2011) Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immunother 60:1161–1171PubMedCrossRef Poschke I, Mougiakakos D, Kiessling R (2011) Camouflage and sabotage: tumor escape from the immune system. Cancer Immunol Immunother 60:1161–1171PubMedCrossRef
15.
Zurück zum Zitat Reck M (2012) What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? Ann Oncol 23(Suppl 8):viii28–viii34PubMed Reck M (2012) What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer? Ann Oncol 23(Suppl 8):viii28–viii34PubMed
16.
Zurück zum Zitat Topalian SL et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454 Topalian SL et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454
17.
Zurück zum Zitat Brahmer JR et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465 Brahmer JR et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465
18.
19.
Zurück zum Zitat Alegre ML, Frauwirth KA, Thompson CB (2001) T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 1:220–228PubMedCrossRef Alegre ML, Frauwirth KA, Thompson CB (2001) T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 1:220–228PubMedCrossRef
20.
Zurück zum Zitat Spadaro M et al (2008) Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells. FASEB J 22:2747–2757CrossRef Spadaro M et al (2008) Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells. FASEB J 22:2747–2757CrossRef
21.
Zurück zum Zitat Digumarti R et al (2011) A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. J Thorac Oncol 6:1098–1103 Digumarti R et al (2011) A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. J Thorac Oncol 6:1098–1103
22.
Zurück zum Zitat Hayes TG et al (2006) Phase I trial of oral talactoferrin alfa in refractory solid tumors. Invest New Drugs 24:233–240PubMedCrossRef Hayes TG et al (2006) Phase I trial of oral talactoferrin alfa in refractory solid tumors. Invest New Drugs 24:233–240PubMedCrossRef
23.
Zurück zum Zitat Parikh PM et al (2011) Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. J Clin Oncol 29:4129–4136 Parikh PM et al (2011) Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. J Clin Oncol 29:4129–4136
24.
Zurück zum Zitat Butts C et al (2005) Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 23:6674–6681 Butts C et al (2005) Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 23:6674–6681
25.
Zurück zum Zitat Nemunaitis J et al (2006) Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 24:4721–4730 Nemunaitis J et al (2006) Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 24:4721–4730
26.
Zurück zum Zitat Nemunaitis J et al (2009) Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther 16:620–624PubMedCrossRef Nemunaitis J et al (2009) Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther 16:620–624PubMedCrossRef
27.
Zurück zum Zitat Kong F et al (1999) Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 86:1712–1719PubMedCrossRef Kong F et al (1999) Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 86:1712–1719PubMedCrossRef
28.
Zurück zum Zitat Caballero OL, Chen YT (2009) Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 100:2014–2021PubMedCrossRef Caballero OL, Chen YT (2009) Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 100:2014–2021PubMedCrossRef
29.
Zurück zum Zitat Bolli M et al (2002) Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg 236:785–793PubMedCrossRefPubMedCentral Bolli M et al (2002) Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg 236:785–793PubMedCrossRefPubMedCentral
30.
Zurück zum Zitat Atanackovic D et al (2008) Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A 105:1650–1655CrossRef Atanackovic D et al (2008) Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci U S A 105:1650–1655CrossRef
31.
Zurück zum Zitat Atanackovic D et al (2004) Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 172:3289–3296 Atanackovic D et al (2004) Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 172:3289–3296
32.
Zurück zum Zitat Grah J et al (2008) Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features. Coll Antropol 32:731–736PubMed Grah J et al (2008) Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features. Coll Antropol 32:731–736PubMed
Metadaten
Titel
Lungenkarzinom
Molekulare Pathologie und personalisierte Therapie
verfasst von
A. Schultheis
J. Wolf
R. Büttner
Publikationsdatum
01.09.2014
Verlag
Springer Vienna
Erschienen in
Wiener klinisches Magazin / Ausgabe 4/2014
Print ISSN: 1869-1757
Elektronische ISSN: 1613-7817
DOI
https://doi.org/10.1007/s00740-014-0006-5

Weitere Artikel der Ausgabe 4/2014

Wiener klinisches Magazin 4/2014 Zur Ausgabe